Copyright © 2001 by the European Society of Cardiology.
Effects of trimetazidine on the contractile response of chronically dysfunctional myocardium to low-dose dobutamine in ischaemic cardiomyopathy
Department of Cardiology, "G.M.Lancisi" Ancona, Italy
revised February 12, 2001; accepted February 15, 2001
Abstract
Background There is evidence that trimetazidine, an antiischaemic agent with a direct cytoprotective effect on the myocardium, is effective in stable angina. However, it is not clear whether trimetazidine can improve the mechanical efficiency of chronically dysfunctional myocardium, and whether this potentially beneficial effect can translate into improvements in left ventricular function as well as functional capacity.
Methods Thirty-eight patients (52·7±8 years) with post-necrotic left ventricular dysfunction (ejection fraction: 33±5%) and multivessel coronary artery disease were studied. Patients were randomized into two matched groups. Group A received trimetazidine (20mg three times daily) for 2 months, while group B received a placebo during the same period. The usual antianginal medications were not altered during the study. At baseline and after 2 months, all patients underwent low-dose dobutamine echocardiography (5–20µg.kg–1.min–1), and a symptom-limited cardiopulmonary exercise test.
Results On initial evaluation, systolic wall thickening score index, heart rate, systolic blood pressure and rate pressure product were similar at rest and peak dobutamine in both groups. However, at 2 months, group A patients had significant improvements in the rest and peak systolic wall thickening score index (13% and 20·7%, P<0·001) and ejection fraction (19·7% and 14·1%, P<0·001) without concomitant changes in heart rate and blood pressure. Peak VO2was also significantly increased in patients taking trimetazidine (15%, P=0·001 vs controls).
Conclusions In patients with ischaemic cardiomyopathy, trimetazidine improves the contractile response of chronically dysfunctional myocardium to dobutamine without haemodynamic changes. This effect was associated with improvements in left ventricular function and peak VO2.
Key Words: Trimetazidine, dysfunctional myocardium, dobutamine-stress echocardiography, contractility
f1 Correspondence: Romualdo Belardinelli, MD, FESC, Azienda Ospedaliera "G.M.Lancisi", Ancona, Italy.
References
- Sellier P. Chronic effects of trimetazidine on ergometric parameters in effort angina. Cardiovasc Drugs Ther. 1990;Suppl 4:822–823[CrossRef]
- Dalla Volta S, Maraglino G, Della Valentina P, Viena P, Desideri A. Comparison of trimetazidine with nifedipine in effort angina: A double-blind, crossover study. Cardiovasc Drugs Ther. 1990;4:853–860
- Detry JM, Sellier P, Pennaforte S. Trimetazidine: a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Br J Clin Pharmacol. 1994;37:279–288[ISI][Medline]
- Kantor PF, Lucien A, Kozak R, Lopaschuk GD. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res. 2000;86:580–588
[Abstract/Free Full Text] - Renaud JF. Internal pH, Na+ and Ca++ regulation by trimetazidine during cardiac cell acidosis. Cardiovasc Drugs Ther. 1988;1:677–686[CrossRef][Medline]
- Lavanchy N, Martin J, Rossi A. Anti-ischemic effects of trimetazidine: 31P-NMR spectroscopy in the isolated rat heart. Arch Int Pharmacodyn. 1987;286:97–110
- Lu C, Dabrowski P, Fragasso G, Chierchia S. Effects of trimetazidine on ischemic left ventricular dysfunction in patients with coronary artery disease. Am J Cardiol. 1998;82:898–901[CrossRef][ISI][Medline]
- Schiller NB, Shah PM, Crawford M. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography: American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of two-dimensional Echocardiograms. J Am Soc Echocardiogr. 1989;2:358–367[Medline]
- Belardinelli R, Georgiou D, Purcaro A. Low-dose dobutamine echocardiography predicts improvement in functional capacity after exercise training in patients with ischemic cardiomyopathy: prognostic implication. J Am Coll Cardiol. 1998;31:1027–1034
[Abstract/Free Full Text] - Aussedat J, Ray A, Kay L, Verdys M, Harpey C, Rossi A. Improvement of long-term preservation of isolated arrested rat heart: beneficial effect of the antiischemic agent trimetazidine. J Cardiovasc Pharmacol. 1993;21:128–135[ISI][Medline]
- Vanoverschelde JJL, Wijns W, Deprè C. Mechanisms of chronic regional postischemic dysfunction in humans. Circulation. 1993;87:1513–1523
[Abstract/Free Full Text] - Panza JA, Dilsizian V, Laurienzo JM, Curiel RV, Katsiyannis PT. Relation between thallium uptake and contractile response to dobutamine: implications regarding myocardial viability in patients with chronic coronary artery disease and left ventricular dysfunction. Circulation. 1995;81:990–998
- Guarnieri C, Muscari C. Effect of trimetazidine on mitochondrial function and oxidative damage during reperfusion of ischemic hyperthrofied myocardium. Pharmacology. 1993;46:324–331[ISI][Medline]
- Cave AC, Eberli FR, Ngoy S, Rose J, Ingwall JS, Apstein CS. Increased glycolytic substrate protects against ischemic diastolic dysfunction: 31P-NMR studies in the isolated blood perfused rat heart. Circulation. 1993;88:I-43–I-49
- Brottier L, Barat JL, Combe C, Boussens B, Bonnet J, Bricaud H. Therapeutic value of a cardioprotective agent in patients with severe ischaemic cardiomyopathy. Eur Heart J. 1990;11:207–212
[Abstract/Free Full Text]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. Belardinelli, M. Solenghi, L. Volpe, and A. Purcaro Trimetazidine improves endothelial dysfunction in chronic heart failure: an antioxidant effect Eur. Heart J., May 1, 2007; 28(9): 1102 - 1108. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Labinskyy, M. Bellomo, M. P. Chandler, M. E. Young, V. Lionetti, K. Qanud, F. Bigazzi, T. Sampietro, W. C. Stanley, and F. A. Recchia Chronic Activation of Peroxisome Proliferator-Activated Receptor-{alpha} with Fenofibrate Prevents Alterations in Cardiac Metabolic Phenotype without Changing the Onset of Decompensation in Pacing-Induced Heart Failure J. Pharmacol. Exp. Ther., April 1, 2007; 321(1): 165 - 171. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Fragasso, A. Palloshi, P. Puccetti, C. Silipigni, A. Rossodivita, M. Pala, G. Calori, O. Alfieri, and A. Margonato A Randomized Clinical Trial of Trimetazidine, a Partial Free Fatty Acid Oxidation Inhibitor, in Patients With Heart Failure J. Am. Coll. Cardiol., September 5, 2006; 48(5): 992 - 998. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. D. Lopaschuk Optimizing cardiac Fatty Acid and glucose metabolism as an approach to treating heart failure. Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 2006; 10(3): 228 - 230. [Abstract] [PDF]
|
|
|
|
|
|
G. Fragasso, G. Perseghin, F. De Cobelli, A. Esposito, A. Palloshi, G. Lattuada, P. Scifo, G. Calori, A. Del Maschio, and A. Margonato Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure Eur. Heart J., April 2, 2006; 27(8): 942 - 948. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Lee, R. Campbell, M. Scheuermann-Freestone, R. Taylor, P. Gunaruwan, L. Williams, H. Ashrafian, J. Horowitz, A. G. Fraser, K. Clarke, et al. Metabolic Modulation With Perhexiline in Chronic Heart Failure: A Randomized, Controlled Trial of Short-Term Use of a Novel Treatment Circulation, November 22, 2005; 112(21): 3280 - 3288. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. C. Stanley, F. A. Recchia, and I. C. Okere Metabolic therapies for heart disease: Fish for prevention and treatment of cardiac failure? Cardiovasc Res, November 1, 2005; 68(2): 175 - 177. [Full Text] [PDF]
|
|
|
|
 |
|
 W. C. Stanley, F. A. Recchia, and G. D. Lopaschuk Myocardial Substrate Metabolism in the Normal and Failing Heart Physiol Rev, July 1, 2005; 85(3): 1093 - 1129. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P Di Napoli, A A Taccardi, and A Barsotti Long term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischaemic dilated cardiomyopathy Heart, February 1, 2005; 91(2): 161 - 165. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Vitale, M. Wajngaten, B. Sposato, O. Gebara, P. Rossini, M. Fini, M. Volterrani, and G. M.C. Rosano Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease Eur. Heart J., October 2, 2004; 25(20): 1814 - 1821. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Lee, J. Horowitz, and M. Frenneaux Metabolic manipulation in ischaemic heart disease, a novel approach to treatment Eur. Heart J., April 2, 2004; 25(8): 634 - 641. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D.V. Cokkinos Can metabolic manipulation reverse myocardial dysfunction? Eur. Heart J., December 1, 2001; 22(23): 2138 - 2139. [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||